<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03660813</url>
  </required_header>
  <id_info>
    <org_study_id>4689-17-SMC</org_study_id>
    <nct_id>NCT03660813</nct_id>
  </id_info>
  <brief_title>Follicle Size and Oocyte Development</brief_title>
  <acronym>AMJH</acronym>
  <official_title>The Effect of Triggering on the Quantitative Assessment of Follicle Size on Oocyte Development</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies have shown that the follicles greater in diameter was most likely to have a mature&#xD;
      oocyte that was capable of fertilization and best suited for development into a high-quality&#xD;
      embryo. Smaller follicles showed lower rates ( 60%).&#xD;
&#xD;
      Lately new triggering protocols have emerged aiming to improve the proportion of mature&#xD;
      oocytes at the time of retrieval. The aim of this study is to learn the effects of the dual&#xD;
      triggering compared to the standard hCG triggering on the oocyte development and quality as a&#xD;
      function of the follicle size&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Controlled ovarian hyperstimulation is critical to assisted reproduction because it increases&#xD;
      the number of oocytes undergoing development. The medications, designed to override the&#xD;
      selection of a single dominant follicle, drive multiple antral follicles into the growth&#xD;
      phase. These follicles grow at different rates, and management is guided by their size rather&#xD;
      than their competence. Human chorionic gonadotropin (hCG) is usually used as a surrogate LH&#xD;
      surge to induce luteinization of the granulosa cells, final oocyte maturation and resumption&#xD;
      of meiosis. This treatment is therefore based on an assumption that follicular size predicts&#xD;
      the developmental competence of the oocyte. The outcome, is that only a portion of the&#xD;
      oocytes will be competent for fertilization and development into viable embryos.&#xD;
&#xD;
      Studies have shown that the follicles greater in diameter was most likely to have a mature&#xD;
      oocyte that was capable of fertilization and best suited for development into a high-quality&#xD;
      embryo. Smaller follicles showed lower rates ( 60%).&#xD;
&#xD;
      Lately new triggering protocols have emerged aiming to improve the proportion of mature&#xD;
      oocytes at the time of retrieval. Following the observations demonstrating comparable or even&#xD;
      better oocyte\embryos quality following GnRHa, compared to hCG trigger, and the different&#xD;
      effects of LH and hCG on the downstream signaling of the LH receptor, GnRHa is now offered&#xD;
      concomitant to the standard hCG trigger dose to improve oocyte/embryo yield and quality. To&#xD;
      the best of our knowledge, no studies have been done comparing the effect of the dual&#xD;
      triggering on the amount of larger follicles per cycle and its effect on oocyte maturation.&#xD;
&#xD;
      The aim of this study is to learn the effects of the dual triggering compared to the standard&#xD;
      hCG triggering on the oocyte development and quality as a function of the follicle size&#xD;
&#xD;
      Material and Methods A prospective cohort study including all women on antagonist protocol&#xD;
      for controlled ovarian hyper stimulation with triggering using Ovitrelle ( hCG 250 mcg) or&#xD;
      dual triggering - Ovitrelle ( Hcg 250 mcg) + Decapeptyl ( GnRH Agonist 0.1 mg*2 ).&#xD;
&#xD;
      As practiced at the IVF clinic, individuals will be monitored with transvaginal ultrasound&#xD;
      and blood samples for hormonal profile ( including Estradiol, Progesteron, FSH). The decision&#xD;
      to administer hCG or Dual triggering will be based on physician judgment, and the timing will&#xD;
      be based on the lead follicular cohort, usually with at least two follicles measuring 18 mm&#xD;
      for maximal diameter. A transvaginal, ultrasound-guided follicular aspiration will be&#xD;
      conducted 36 hours after triggering administration. At retrieval, each follicle will be&#xD;
      measured before aspiration. Follicles will be divided into five arbitrary follicular groups&#xD;
      according to their maximal dimensional size: &gt;18 mm, 16 to 18 mm, 13 to 15 mm, 10 to 12 mm,&#xD;
      and &lt;10 mm. Following identification, the follicles will be aspirated. Microscopic&#xD;
      examination of the follicular aspirates will be performed by the embryologist. Once the&#xD;
      oocytes will be identified, they will be collected and organized according to follicle size.&#xD;
      Oocytes will be fertilized using conventional insemination or intracytoplasmic sperm&#xD;
      injection (ICSI) . Each embryo will be cultured and evaluated after 72 hours.&#xD;
&#xD;
      Day-3 embryo grading, based on cellular cleavage and fragmentation, will be recorded&#xD;
      separately. Fragmentation will be scored by the degree of fragmentation proportional to the&#xD;
      whole embryo volume: 1, no fragmentation; 2, &lt;10%; 3, 10% to 25%; 4, 25% to 50%; 5, &gt;50%. The&#xD;
      information for each oocyte, starting from the follicular size, will be followed through all&#xD;
      laboratory procedures including insemination, oocyte stripping for ICSI, ICSI, pronuclear&#xD;
      assessment, embryo culture, and embryo transfer.&#xD;
&#xD;
      Data will be collected from the medical file of each patient.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Oocyte retrieved in each of the follicular size groups</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Number of oocyte retrieved in each of the follicular groups divided according to the maximal dimensional size</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metaphase II oocytes (MII)</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Oocyte undergone nuclear maturation -Metaphase II oocytes (MII)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fertilization rate</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Fertilization rate ( 2 pronuclear)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Top Quality Embryo</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Top Quality Embryo - Day-3 embryo with 3-4 cells with of to 15% fragmentation rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>IVF Treatment</condition>
  <arm_group>
    <arm_group_label>HCG triggering</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ovitrelle ( hCG 250 mcg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dual triggering</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ovitrelle ( Hcg 250 mcg) + Decapeptyl ( GnRH Agonist 0.1 mg*2 )</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Follicle measurment</intervention_name>
    <description>Follicle will be measured before aspiration</description>
    <arm_group_label>Dual triggering</arm_group_label>
    <arm_group_label>HCG triggering</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ovitrelle ( Hcg 250 mcg)</intervention_name>
    <description>Drug used for triggering</description>
    <arm_group_label>Dual triggering</arm_group_label>
    <arm_group_label>HCG triggering</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decapeptyl ( GnRH Agonist 0.1 mg*2 )</intervention_name>
    <description>Drug used for triggering</description>
    <arm_group_label>Dual triggering</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age- 18-45&#xD;
&#xD;
          2. Antagonist protocol&#xD;
&#xD;
          3. Triggering: A- with Ovitrelle ( HCG) 250 mcg B- with dual triggering - Ovitrelle (&#xD;
             HCG) 250 mcg + Decapeptyl ( GnRH Agonist ) 0.1 mg*2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Endometriosis&#xD;
&#xD;
          2. Known mutation of Fragile X&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Only women during IVF treatment</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Aya Mohr Sasson, M.D</last_name>
    <phone>972-3-5302777</phone>
    <email>mohraya@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jigal Haas, M.D</last_name>
    <phone>972-3-5302777</phone>
    <email>jigalh@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aya Mohr Sasson, M.D</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <results_reference>
    <citation>Miller KF, Goldberg JM, Falcone T. Follicle size and implantation of embryos from in vitro fertilization. Obstet Gynecol. 1996 Oct;88(4 Pt 1):583-6.</citation>
    <PMID>8841223</PMID>
  </results_reference>
  <results_reference>
    <citation>Orvieto R. Triggering final follicular maturation-hCG, GnRH-agonist or both, when and to whom? J Assist Reprod Genet. 2016 Oct;33(10):1415-1416. Epub 2016 Jul 22.</citation>
    <PMID>27448022</PMID>
  </results_reference>
  <results_reference>
    <citation>Andersen CY. Characteristics of human follicular fluid associated with successful conception after in vitro fertilization. J Clin Endocrinol Metab. 1993 Nov;77(5):1227-34.</citation>
    <PMID>7521343</PMID>
  </results_reference>
  <results_reference>
    <citation>Rosen MP, Shen S, Dobson AT, Rinaudo PF, McCulloch CE, Cedars MI. A quantitative assessment of follicle size on oocyte developmental competence. Fertil Steril. 2008 Sep;90(3):684-90. doi: 10.1016/j.fertnstert.2007.02.011. Epub 2008 Feb 4.</citation>
    <PMID>18249377</PMID>
  </results_reference>
  <results_reference>
    <citation>Bergh C, Broden H, Lundin K, Hamberger L. Comparison of fertilization, cleavage and pregnancy rates of oocytes from large and small follicles. Hum Reprod. 1998 Jul;13(7):1912-5.</citation>
    <PMID>9740448</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 4, 2018</study_first_submitted>
  <study_first_submitted_qc>September 4, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2018</study_first_posted>
  <last_update_submitted>April 7, 2020</last_update_submitted>
  <last_update_submitted_qc>April 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sheba Medical Center</investigator_affiliation>
    <investigator_full_name>Dr. Aya Mohr-Sasson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>oocyte, double triggering, follicle size</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan for sharing the data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

